awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q35231826-F541E751-EB67-4AD6-BDD5-33593485C0E4
Q35231826-F541E751-EB67-4AD6-BDD5-33593485C0E4
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35231826-F541E751-EB67-4AD6-BDD5-33593485C0E4
Combined treatment with silibinin and either sorafenib or gefitinib enhances their growth-inhibiting effects in hepatocellular carcinoma cells.
P2860
Q35231826-F541E751-EB67-4AD6-BDD5-33593485C0E4
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35231826-F541E751-EB67-4AD6-BDD5-33593485C0E4
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
966528fce6da87a67c64b3b0add2cb5df3955829
P2860
Inhibitory effect of silibinin on ligand binding to erbB1 and associated mitogenic signaling, growth, and DNA synthesis in advanced human prostate carcinoma cells.